Recce Pharmaceuticals submits clinical trial data for R327G
Recce Pharmaceuticals (ASX:RCE) submitted blinded data from 75 patients to an independent committee to evaluate its topical gel treatment for diabetic foot ulcer infections.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Recce Pharmaceuticals (ASX:RCE) submitted blinded data from 75 patients to an independent committee to evaluate its topical gel treatment for diabetic foot ulcer infections.
PLS (ASX:PLS) announced a proposal to offer up to US$700 million in senior unsecured notes to qualified institutional buyers.
PolyNovo (ASX:PNV) announced CFO Jan Gielen will step down after nearly eight years with the company to pursue a new opportunity.
Starpharma (ASX:SPL) increased its equity interest in Petalion Therapeutics to 66%.
Percheron Therapeutics (ASX:PER) has entered into a preclinical research collaboration with Invion (ASX:IVX) to evaluate its clinical-stage antibody HMBD-002.
Pacific Edge (ASX:PEB) reported progress in its US commercial recovery strategy after securing proposed Medicare price hikes of up to 39%.
Pro Medicus (ASX:PME) signed a seven-year, $24 million deal with US-based Billings Clinic – Logan Health for its cloud platform.
Wesfarmers (ASX:WES) is reportedly set to lose four profitable Priceline pharmacy leases and about $25 million in annual sales to rival Chemist Warehouse.
McPherson's (ASX:MCP) announced on Oct. 19 that Managing Director and CEO Brett Charlton will step down after leading the company for more than three years.
Cell therapy developer Mesoblast (ASX:MSB) reported a 44% increase in first-quarter net revenue from Ryoncil sales to US$28 million.
Mayne Pharma (ASX:MYX) has settled its US patent litigation with Teva Pharmaceuticals USA over generic versions of the menopause treatment IMVEXXY.
Dimerix (ASX:DXB) reached a clinical milestone after the first 100 patients finished two years of double-blind treatment in its global ACTION3 Phase 3 trial.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade